BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804)

PURPOSE: On the basis of evidence that resistance to vascular endothelial growth factor (VEGF) receptor inhibition is caused by hypoxia-driven residual VEGF and other proangiogenic factors, combinations of agents from these classes were hypothesized to improve treatment outcomes relative to single-a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Flaherty, Keith T., Manola, Judith B., Pins, Michael, McDermott, David F., Atkins, Michael B., Dutcher, Janice J., George, Daniel J., Margolin, Kim A., DiPaola, Robert S.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2015
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4500832/
https://ncbi.nlm.nih.gov/pubmed/26077237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.60.9727
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki